ACET

Adicet Bio Inc

3.42

Oct 30 • 3:59 PM ET -0.16 (-4.47%)

3.42

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: INAB FATE CABA KYTX ALLO CRBU NKTX SANA IPSC CRSP

| Held by: VTI VXF IWC DFMC DFAS AVSC BTEC DXUV CHNA

Scroll to Statements

Index	-
Market Cap	32.02M
Enterprise Value	-73.32M
Income	-98.97M
Sales	0.00M
Book/sh	12.83
Cash/sh	12.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	102
IPO	Jan 26, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.27
P/C	0.27
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.71
Current Ratio	6.71
Debt/Eq	0.11
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-11.53
EPS next Y	-4.04
EPS next Q	-1.58
EPS this Y	62.49%
EPS next Y	36.47%
EPS next 5Y	63.23%
EPS past 3/5Y	14.57% 26.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	44.73%
Sales Y/Y TTM	-
EPS Q/Q	63.75%
Sales Q/Q	-
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-17.61% -

Insider Own	12.22%
Insider Trans	0.00%
Inst Own	54.41%
Inst Trans	0.94%
ROA	-63.62%
ROE	-78.08%
ROIC	-76.04%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-28.65%
SMA50	-52.14%
SMA200	-55.53%
Trades

Shs Outstand	9.36M
Shs Float	8.22M
Short Float	6.35%
Short Ratio	2.68
Short Interest	0.52M
52W High	12.96 -73.60%
52W Low	3.56 -3.93%
Volatility	7.37% 8.00%
ATR (14)	0.44
RSI (14)	18.52
Beta	1.62
Rel Volume	1.24
Avg Volume	194.97K
Volume	242,500

Perf Week	-14.29%
Perf Month	-48.49%
Perf Quarter	-62.99%
Perf Half Y	-58.29%
Perf YTD	-59.38%
Perf Year	-72.58%
Perf 3Y	-83.68%
Perf 5Y	-97.51%
Perf 10Y	-
Recom	1.00
Target Price	34.83
Prev Close	3.58
Price	3.42
Change %	-4.47%

Consensus

Strong Buy

Avg. Price Target

$34.83

Implied Upside

+918.4%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 05, 2026	Resumed	JJefferies	Buy	$19	+455.6%
Sep 30, 2024	Resumed	GGuggenheim	Buy	$7	+104.7%
Sep 11, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral
Jun 27, 2023	Downgrade	JJMP Securities	Mkt Outperform → Mkt Perform
Jun 27, 2023	Downgrade	GGuggenheim	Buy → Neutral
Jun 01, 2023	Downgrade	JJP Morgan	Overweight → Neutral	$20 → $6	+75.4%
Sep 21, 2022	Initiated	JJP Morgan	Overweight	$23	+572.5%
Mar 31, 2022	Initiated	SSMBC Nikko	Outperform	$28	+718.7%
Mar 08, 2022	Initiated	TTruist	Buy	$30	+777.2%
Mar 04, 2022	Initiated	JJefferies	Buy	$27	+689.5%
May 18, 2021	Initiated	BBTIG Research	Buy	$34	+894.2%
Apr 23, 2021	Initiated	HH.C. Wainwright	Buy	$27	+689.5%
Apr 14, 2021	Initiated	CCanaccord Genuity	Buy	$28	+718.7%
Apr 08, 2021	Initiated	GGuggenheim	Buy	$22	+543.3%
Nov 04, 2020	Initiated	RB. Riley Securities	Buy	$30	+777.2%
Oct 27, 2020	Initiated	JJMP Securities	Mkt Outperform	$30	+777.2%
Oct 16, 2020	Initiated	WWedbush	Outperform	$25	+631.0%

Oct-30-26 05:38PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-22-26 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire) -6.78%
Sep-30-26 07:12PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Sep-28-26 10:54AM	Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance (InvestorsHub) -29.60%
08:13AM	Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients (InvestorsHub)
06:45AM	Loading…
06:45AM	Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis (Business Wire)
Sep-25-26 04:00PM	Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis (Business Wire) +9.07%
Sep-02-26 04:00PM	Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Sep-01-26 07:00AM	Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update (Business Wire) +6.44%
Aug-31-26 05:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-26 04:00PM	Adicet Bio Announces FDA Clearance of IND Application for ADI-212 (Business Wire)
Aug-05-26 04:15PM	Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire) -13.43%
Jul-21-26 04:00PM	Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference (Business Wire) +5.54%
May-14-26 04:00PM	Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference (Business Wire) -8.68%
May-13-26 04:01PM	Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
04:00PM	Loading…
Mar-12-26 04:00PM	Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress (Business Wire) -5.76%
Jan-30-26 07:00AM	Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire) -6.00%
Jan-07-26 07:00AM	Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones (Business Wire)
Dec-26-25 08:30AM	Adicet Bio Announces Reverse Stock Split (Business Wire)
Nov-28-25 02:23PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.85%
Nov-05-25 04:01PM	Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-31-25 04:59PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-28-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference (Business Wire) -5.12%
Oct-16-25 07:00AM	Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) (Business Wire) +5.49%
Oct-07-25 09:40AM	Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? (Zacks) -14.69%
07:01AM	Adicet Bio, Inc. Announces $80 Million Registered Direct Offering (Business Wire)
06:45AM	Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) (Business Wire)
Sep-30-25 04:27PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-02-25 07:00AM	Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
04:48PM	Loading…
Aug-29-25 04:48PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.09%
Aug-12-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's Why (Zacks) +7.14%
Aug-07-25 04:01PM	Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.62%
Aug-06-25 04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference (Business Wire)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-25-25 07:27AM	Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 (Clinical Trials Arena)
Jul-24-25 07:00AM	Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
May-21-25 04:00PM	Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference (Business Wire) -6.59%
May-09-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks) +27.49%
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.44% -18.65%
Apr-30-25 04:47PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.41% -5.07%
07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-28-25 04:30PM	Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire) +5.82%
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire) -7.96%
Mar-31-25 05:12PM	Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.06%
07:00AM	Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Mar-23-25 08:43AM	Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-06-25 04:01PM	Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Business Wire) -5.90%
Mar-03-25 07:00AM	Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Business Wire) -5.70%
Feb-27-25 08:36AM	Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 (Investing.com)
07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) (Business Wire)
Feb-05-25 07:10AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (Business Wire) +9.79%
Jan-31-25 06:06PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-08-25 04:10PM	Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones (Business Wire)
Dec-31-24 04:48PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Dec-19-24 07:00AM	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Dec-18-24 07:00AM	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer (Business Wire) -6.28%
Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)
Apr-01-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 20 '26	Buy	7.27	74,751	543,440	1,182,624	Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 19 '26	Buy	7.21	74,268	535,472	1,107,873	Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 18 '26	Buy	7.04	74,577	525,022	1,033,605	Apr 13 05:20 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 08 '26	Sale	6.42	72,939	468,082	0	Apr 09 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 07 '26	Sale	6.52	31,719	206,765	32,523	Apr 09 05:38 PM
OrbiMed Genesis Master Fund, L	Shareholder	Apr 09 '26	Proposed Sale	6.55	78,499	514,168		Apr 09 05:34 PM
OrbiMed Israel Partners II, L.	Shareholder	Apr 08 '26	Proposed Sale	6.55	40,416	264,725		Apr 08 08:14 PM
OrbiMed Israel Partners Limite	Shareholder	Apr 07 '26	Proposed Sale	6.43	64,242	413,076		Apr 07 08:46 PM

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

CPAMr. Chen Schor BA

Senior VP & Chief Scientific OfficerDr. Blake Aftab Ph.D.

Ph.D.Dr. Lloyd Klickstein M.D.

Chief Financial OfficerMr. Brian Nicholas Harvey M.B.A.

Chief Technology OfficerDr. Donald Healey Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACET

Adicet Bio Inc

Upgrade your Finviz experience